Table 4.
Univariate and multivariate Cox regression analysis of the gene signature and survival of NSCLC patients in TCGA cohort
| Variables | Group | Patients (N) |
Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| DFS | ||||||
| Age | ≤ 67/> 67 | 383/378 | 0.97 (0.75–1.26) | 8.30E−01 | 1.11 (0.85–1.45) | 4.30E−01 |
| Gender | Female/male | 326/435 | 0.96 (0.74–1.25) | 7.60E−01 | 1.08 (0.81–1.43) | 6.00E−01 |
| Stage | I/II | 410/220 | 1.64 (1.21–2.22) | 1.30E−03 | 1.74 (1.28–2.37) | 3.60E−04 |
| Stage | I/III | 410/109 | 2.16 (1.51–3.08) | 2.20E−05 | 2.25 (1.57–3.22) | 9.30E−06 |
| Stage | I/IV | 410/22 | 1.76 (0.82–3.80) | 1.50E−01 | 1.56 (0.71–3.40) | 2.70E−01 |
| Histological type | Adeno/squamous | 395/366 | 0.65 (0.50–0.85) | 1.60E−03 | 0.58 (0.43–0.77) | 1.60E−04 |
| Risk score | Low/high | 380/381 | 1.33 (1.02–1.73) | 3.70E−02 | 1.40 (1.08–1.83) | 1.30E−02 |
| OS | ||||||
| Age | ≤ 67/> 67 | 383/378 | 1.25 (0.98–1.58) | 7.10E−02 | 1.34 (1.05–1.70) | 1.90E−02 |
| Gender | Female/male | 326/435 | 1.22 (0.96–1.57) | 1.10E−01 | 1.19 (0.92–1.53) | 2.00E−01 |
| Stage | I/II | 410/220 | 1.51 (1.14–2.00) | 4.30E−03 | 1.45 (1.09–1.93) | 1.10E−02 |
| Stage | I/III | 410/109 | 2.07 (1.50–2.85) | 9.60E−06 | 2.04 (1.47–2.83) | 1.80E−05 |
| Stage | I/IV | 410/22 | 2.77 (1.59–4.83) | 3.20E−04 | 2.83 (1.60–5.00) | 3.40E−04 |
| Histological type | Adeno/squamous | 395/366 | 1.13 (0.89–1.44) | 3.20E−01 | 0.93 (0.71–1.22) | 5.90E−01 |
| Risk score | Low/high | 380/381 | 1.54 (1.20–1.96) | 5.50E−04 | 1.48 (1.14–1.91) | 3.30E−03 |
HR: hazard ratio; CI: confidence interval; Adeno: adenocarcinoma; Squamous: squamous cell carcinoma